NOTCH1 activating variants identify a high-risk subgroup of adenoid cystic carcinoma in a nationwide Japanese cohort
Adenoid cystic carcinoma (ACC) follows a heterogeneous clinical course, and because systemic therapies have limited efficacy, active surveillance is offered to selected patients, yet no validated molecular biomarker guides the choice between surveillance and intensive treatment. We retrospectively analyzed comprehe...